Skip to content
Opening soonHORIZON-MISS-2027-02-CANCER-03HaDEAOne-off

Phase 1 including first-in-human clinical trials to test biomarker-guided medicines or multi-modal treatment interventions for patients with rare or very rare cancers or cancer subtypes

Phase 1 trials for rare cancers.

Horizon Europe research and innovation action (€24 million, lump sum) under the EU Mission on Cancer for phase 1 trials, including first-in-human, with biomarker-guided medicines or multi-modal treatments for rare cancers.

Opening soon
84
days until opening
Opens on 10 February 2027
HORIZON-MISS-2027-02-CANCER-03
View all deadlines
Beta

This grant database is in beta

Until the official launch on 1 January 2027 we are making the final improvements. Our editors check every scheme, but details may still be incomplete or out of date. Check the official publication before you apply.

In brief

What is Phase 1 including first-in-human clinical trials to test biomarker-guided medicines or multi-modal treatment interventions for patients with rare or very rare cancers or cancer subtypes?

Who
A consortium of at least three independent organisations from three different EU Member States or Associated Countries, at least one of which is from a Member State. Companies of any size, research organisations, public authorities, foundations and associations can participate.
General Annex B (Entities eligible to participate; Entities eligible for funding; Consortium composition)
What for
A research and innovation action with phase 1 trials, including first-in-human clinical trials, to test biomarker-guided medicines or multi-modal treatments and thereby offer new treatment options for patients with rare or very rare cancers.
Topic HORIZON-MISS-2027-02-CANCER-03 (Expected Outcome; Scope)
What you get
A lump sum grant of up to 100% of eligible costs; the Commission considers an EU contribution of €7 million to €9 million per project appropriate. The indicative budget for the topic is €24 million, expected to fund 3 projects.
Topic HORIZON-MISS-2027-02-CANCER-03 (Expected EU contribution per project; Indicative budget; Legal and financial set-up); General Annex G, Funding rates
What you need to do
Submit a proposal in a single stage via the Funding & Tenders Portal from 10 February 2027 until 16 September 2027 at the latest (17:00 Brussels time), with application form Part A and B, a detailed budget table for the lump sum, an annex on the clinical trial(s) and evidence of advice from regulatory authorities on the design of those trials. Independent experts evaluate and rank the proposals; results are expected around 5 months after the deadline.
Call HORIZON-MISS-2027-02 overview (Opening; Deadline); General Annexes E and F

Built from the details on this page, with nothing added by us.

Purpose & impact

Why does this scheme exist?

New treatment options for patients with rare cancers.

01
Access to targeted treatments
Patients with rare or very rare cancers gain access to promising biomarker-guided medicines or multi-modal treatments through follow-up trials or compassionate use programmes.
02
Opportunities for validation and commercialisation
Researchers, clinicians, start-ups, spin-offs, SMEs, funds and other professionals gain access to innovative technology, medical devices or medicines for further validation or commercialisation.
03
Early evidence for healthcare policy
Healthcare providers and policymakers have early evidence on safety and efficacy to further test affordable biomarker-guided medicines or multi-modal treatments for rare cancers.
Description

About the scheme

Compiled from passages of the scheme's official publication, with nothing added by us.

Proposals under this topic should aim to deliver results that are directed and tailored towards, and contribute to all of the following expected outcomes: - Patients with rare or very rare cancers or cancer subtypes have access to tailored, promising biomarker-guided medicines or multi-modal treatment interventions via participation in subsequent clinical trials or national or regional compassionate use programmes by health authorities; - Researchers, physicians, innovators, startup, spin-off and spin-out companies, SMEs, charities or foundations and other professionals from different disciplines and sectors have access to innovative technology, medical devices or promising biomarker-guided medicines for further validation or commercialisation; - National healthcare providers, policymakers and authorities in European regions, EU Member States and Associated Countries have early safety and efficacy evidence to support further testing of affordable biomarker-guided medicines or multi-modal treatment interventions that benefit patients with rare or very rare cancers in their healthcare systems;

Am I eligible?

Conditions

Quoted verbatim from the scheme, with the article that sets each condition.

01
To be eligible for funding, applicants must be established in one of the following countries: – the Member States of the European Union, including their outermost regions: … – countries associated to Horizon Europe
02
Unless otherwise provided for in the specific call/topic conditions, only legal entities forming a consortium are eligible to participate in actions provided that the consortium includes, as beneficiaries, three legal entities independent from each other and each established in a different country as follows: – at least one independent legal entity established in a Member State; and – at least two other independent legal entities, each established in different Member States or Associated Countries.
03
Applications will only be considered eligible if their content corresponds, wholly or in part, to the topic description for which it is submitted.
All sizes
Micro< 10 FTE
Small< 50 FTE
Medium< 250 FTE
Large≥ 250 FTE
Themes
Onderzoek, ontwikkeling en innovatieGezondheid, zorg en welzijn
Project phase
ResearchDevelopment
Funding

What do you get?

100% of your eligible project costs.

Note on the maximum
No binding maximum; the Commission considers an EU contribution of €7-9 million per project appropriate (other amounts not excluded).
€24m · Indicative topic budget, expected to fund 3 projects.
Budget status
Not published by the source
The sources do not say how much budget is left (checked 18 November 2026).
No double funding: an action may receive only one grant from the EU budget (except EU Synergy grants) and the same costs may never be declared under two different EU actions (General Annex G).
Type
Direct grant (non-repayable)
Calendar

Deadlines & cycles

10
FEB
HORIZON-MISS-2027-02-CANCER-03 opens 10 February 2027
Call HORIZON-MISS-2027-02, overview of this call
Cycle: Evaluation results around 5 months after the deadline; signature of the grant agreement around 8 months after the deadline (General Annex F). General Annex F, Indicative timetable for evaluation and for signature of the grant agreement
Application

How do you apply?

Pre-registration
Required, before the full application
Required attachments
  • Application form Part A: administrative data of the participants and summarised budget (to be completed online)
  • Application form Part B: technical description of the project (PDF, maximum 45 pages)
  • Detailed budget table (HE LS template) for the lump sum contribution
  • Annex with information on the clinical trial(s) (HE template)
  • Evidence of advice from regulatory authorities on the design of the clinical trial(s)
Procedure
Apply via the Funding & Tenders Portal with an EU Login and a PIC number; single-stage; deadline 17:00 Brussels time; managed by the European Health and Digital Executive Agency (HaDEA).
Eligible costs

What can the money be spent on?

Personnel costs
Materials
Not eligible
Subcontracting
Equipment
Land
Not eligible
Buildings
Not eligible
Overheads
Travel costs
Other costs
Lump sum: fixed contribution per work package, no cost reporting (lump sum decision of 7 July 2021).
Downloads

Files & forms

Changes

What has changed?

10 November 2026scheme · version 5

Subtitle
Subtitle: ChangedShow
Before

Fase 1-studies voor zeldzame kankers.

Now

Phase 1 trials for rare cancers.

Description
Description: ChangedShow
Before

Projecten voeren fase 1-klinische studies uit, inclusief eerste toepassing bij mensen, om biomarkergestuurde geneesmiddelen of multimodale behandelingen te testen bij patiënten met zeldzame of zeer zeldzame kankers of subtypen. Hogere drempels bij de beoordeling: 4 per criterium en 12 in totaal.

Now

Projects conduct phase 1 clinical trials, including first-in-human use, to test biomarker-guided medicines or multi-modal treatments in patients with rare or very rare cancers or cancer subtypes. Higher evaluation thresholds: 4 per criterion and 12 overall.

Short description
Short description: ChangedShow
Before

Horizon Europe onderzoeks- en innovatieactie (€ 24 mln, lump sum) binnen de EU-missie Kanker voor fase 1-studies, inclusief first-in-human, met biomarkergestuurde geneesmiddelen of multimodale behandelingen bij zeldzame kankers.

Now

Horizon Europe research and innovation action (€24 million, lump sum) under the EU Mission on Cancer for phase 1 trials, including first-in-human, with biomarker-guided medicines or multi-modal treatments for rare cancers.

Cycle
Cycle: ChangedShow
Before

Uitslag van de evaluatie rond 5 maanden na de deadline; ondertekening van de subsidieovereenkomst rond 8 maanden na de deadline (General Annex F).

Now

Evaluation results around 5 months after the deadline; signature of the grant agreement around 8 months after the deadline (General Annex F).

Note on the total budget
Note on the total budget: ChangedShow
Before

Indicatief topicbudget, naar verwachting 3 projecten.

Now

Indicative topic budget, expected to fund 3 projects.

Note on the maximum
Note on the maximum: ChangedShow
Before

Geen bindend maximum; de Commissie acht € 7 tot 9 mln EU-bijdrage per project passend (andere bedragen niet uitgesloten).

Now

No binding maximum; the Commission considers an EU contribution of €7-9 million per project appropriate (other amounts not excluded).

Cumulation
Cumulation: ChangedShow
Before

Geen dubbele financiering: een actie kan maar één subsidie uit de EU-begroting krijgen (behalve EU Synergy grants) en dezelfde kosten mogen nooit bij twee verschillende EU-acties worden gedeclareerd (General Annex G).

Now

No double funding: an action may receive only one grant from the EU budget (except EU Synergy grants) and the same costs may never be declared under two different EU actions (General Annex G).

Search engine title
Fase 1-studies zeldzame kankers (EU-missie Kanker) becomes Phase 1 trials for rare cancers (EU Mission on Cancer)
Search engine description
Search engine description: ChangedShow
Before

Horizon Europe RIA van € 24 mln voor fase 1- en first-in-human-studies bij zeldzame of zeer zeldzame kankers.

Now

Horizon Europe RIA of €24 million for phase 1 and first-in-human trials in rare or very rare cancers.

Keywords
biomarkergestuurde geneesmiddelen, EU-missie Cancer, fase 1-studies, Horizon Europe, HORIZON-MISS-2027-02-CANCER-03, zeldzame kankers becomes biomarker-guided medicines, EU Mission on Cancer, Horizon Europe, HORIZON-MISS-2027-02-CANCER-03, phase 1 trials, rare cancers
Language
Dutch (Netherlands) becomes British English
Required attachments
Aanvraagformulier deel A: administratieve gegevens van de deelnemers en samengevatte begroting (online in te vullen); Aanvraagformulier deel B: technische beschrijving van het project (pdf, maximaal 45 pagina's); Gedetailleerde begrotingstabel (HE LS-sjabloon) voor de lump-sumbijdrage; Bijlage met informatie over de klinische studie(s) (HE-sjabloon); Bewijs van advies van regelgevende instanties over de opzet van de klinische studie(s) becomes Application form Part A: administrative data of the participants and summarised budget (to be completed online); Application form Part B: technical description of the project (PDF, maximum 45 pages); Detailed budget table (HE LS template) for the lump sum contribution; Annex with information on the clinical trial(s) (HE template); Evidence of advice from regulatory authorities on the design of the clinical trial(s)
Procedure
Procedure: ChangedShow
Before

Aanvragen via het Funding & Tenders Portal met een EU Login en een PIC-nummer; single-stage; deadline 17:00 uur Brusselse tijd; beheerd door European Health and Digital Executive Agency (HaDEA).

Now

Apply via the Funding & Tenders Portal with an EU Login and a PIC number; single-stage; deadline 17:00 Brussels time; managed by the European Health and Digital Executive Agency (HaDEA).

Notes per cost type
Notes per cost type: ChangedShow
Before

Other costs: Lump sum: vaste bijdrage per werkpakket, geen kostenverantwoording (lumpsumbesluit van 7 juli 2021).

Now

Other costs: Lump sum: fixed contribution per work package, no cost reporting (lump sum decision of 7 July 2021).

Why this scheme
Why this scheme: ChangedShow
Before

Nieuwe behandelopties voor patiënten met zeldzame kankers.

Now

New treatment options for patients with rare cancers.

In brief
In brief: ChangedShow
Before

Who: Een consortium van ten minste drie onafhankelijke organisaties uit drie verschillende EU-lidstaten of geassocieerde landen, waarvan minstens één uit een lidstaat. Bedrijven van elke omvang, onderzoeksinstellingen, overheden, stichtingen en verenigingen kunnen deelnemen.

What for: Een onderzoeks- en innovatieactie met fase 1-studies, waaronder first-in-human klinische studies, om biomarkergestuurde geneesmiddelen of multimodale behandelingen te testen en zo nieuwe behandelopties te bieden voor patiënten met zeldzame of zeer zeldzame kankers.

What you get: Een lump-sumsubsidie tot 100% van de subsidiabele kosten; de Commissie acht een EU-bijdrage van € 7 tot € 9 miljoen per project passend. Het indicatieve budget voor het topic is € 24 miljoen, naar verwachting voor 3 projecten.

What you need to do: Dien van 10 februari 2027 tot uiterlijk 16 september 2027 (17:00 uur Brusselse tijd) in één ronde een voorstel in via het Funding & Tenders Portal, met aanvraagformulier deel A en B, een gedetailleerde begrotingstabel voor de lump sum, een bijlage over de klinische studie(s) en bewijs van advies van regelgevende instanties over de opzet van die studies. Onafhankelijke experts beoordelen en rangschikken de voorstellen; de uitslag volgt naar verwachting circa 5 maanden na de deadline.

Now

Who: A consortium of at least three independent organisations from three different EU Member States or Associated Countries, at least one of which is from a Member State. Companies of any size, research organisations, public authorities, foundations and associations can participate.

What for: A research and innovation action with phase 1 trials, including first-in-human clinical trials, to test biomarker-guided medicines or multi-modal treatments and thereby offer new treatment options for patients with rare or very rare cancers.

What you get: A lump sum grant of up to 100% of eligible costs; the Commission considers an EU contribution of €7 million to €9 million per project appropriate. The indicative budget for the topic is €24 million, expected to fund 3 projects.

What you need to do: Submit a proposal in a single stage via the Funding & Tenders Portal from 10 February 2027 until 16 September 2027 at the latest (17:00 Brussels time), with application form Part A and B, a detailed budget table for the lump sum, an annex on the clinical trial(s) and evidence of advice from regulatory authorities on the design of those trials. Independent experts evaluate and rank the proposals; results are expected around 5 months after the deadline.

Goals
Goals: 3 removed, 3 newShow
Removed

Toegang tot gerichte behandelingen Patiënten met zeldzame of zeer zeldzame kankers krijgen toegang tot veelbelovende biomarkergestuurde geneesmiddelen of multimodale behandelingen via vervolgstudies of compassionate-useprogramma's.

Kansen voor validatie en commercialisering Onderzoekers, artsen, start-ups, spin-offs, mkb, fondsen en andere professionals krijgen toegang tot innovatieve technologie, medische hulpmiddelen of geneesmiddelen voor verdere validatie of commercialisering.

Vroeg bewijs voor zorgbeleid Zorgaanbieders en beleidsmakers hebben vroeg bewijs over veiligheid en werkzaamheid om betaalbare biomarkergestuurde geneesmiddelen of multimodale behandelingen voor zeldzame kankers verder te testen.

New

Access to targeted treatments Patients with rare or very rare cancers gain access to promising biomarker-guided medicines or multi-modal treatments through follow-up trials or compassionate use programmes.

Opportunities for validation and commercialisation Researchers, clinicians, start-ups, spin-offs, SMEs, funds and other professionals gain access to innovative technology, medical devices or medicines for further validation or commercialisation.

Early evidence for healthcare policy Healthcare providers and policymakers have early evidence on safety and efficacy to further test affordable biomarker-guided medicines or multi-modal treatments for rare cancers.

Show 4 earlier versions

20 October 2026scheme · version 4

Conditions
Conditions: 2 removed, 3 newShow
Removed

Consortium van minstens drie partners Minstens drie onafhankelijke juridische entiteiten uit drie verschillende EU-lidstaten of geassocieerde landen, waarvan minstens één uit een lidstaat (General Annex B).

Hogere beoordelingsdrempels De drempel is 4 voor Excellence, Impact en Implementation, met een cumulatieve drempel van 12 (afwijking van General Annex D).

New

To be eligible for funding, applicants must be established in one of the following countries: – the Member States of the European Union, including their outermost regions: … – countries associated to Horizon Europe

Unless otherwise provided for in the specific call/topic conditions, only legal entities forming a consortium are eligible to participate in actions provided that the consortium includes, as beneficiaries, three legal entities independent from each other and each established in a different country as follows: – at least one independent legal entity established in a Member State; and – at least two other independent legal entities, each established in different Member States or Associated Countries.

Applications will only be considered eligible if their content corresponds, wholly or in part, to the topic description for which it is submitted.

In brief
In brief: AddedShow
Now

Who: Een consortium van ten minste drie onafhankelijke organisaties uit drie verschillende EU-lidstaten of geassocieerde landen, waarvan minstens één uit een lidstaat. Bedrijven van elke omvang, onderzoeksinstellingen, overheden, stichtingen en verenigingen kunnen deelnemen.

What for: Een onderzoeks- en innovatieactie met fase 1-studies, waaronder first-in-human klinische studies, om biomarkergestuurde geneesmiddelen of multimodale behandelingen te testen en zo nieuwe behandelopties te bieden voor patiënten met zeldzame of zeer zeldzame kankers.

What you get: Een lump-sumsubsidie tot 100% van de subsidiabele kosten; de Commissie acht een EU-bijdrage van € 7 tot € 9 miljoen per project passend. Het indicatieve budget voor het topic is € 24 miljoen, naar verwachting voor 3 projecten.

What you need to do: Dien van 10 februari 2027 tot uiterlijk 16 september 2027 (17:00 uur Brusselse tijd) in één ronde een voorstel in via het Funding & Tenders Portal, met aanvraagformulier deel A en B, een gedetailleerde begrotingstabel voor de lump sum, een bijlage over de klinische studie(s) en bewijs van advies van regelgevende instanties over de opzet van die studies. Onafhankelijke experts beoordelen en rangschikken de voorstellen; de uitslag volgt naar verwachting circa 5 maanden na de deadline.

18 October 2026scheme · version 3

About the scheme
About the scheme: AddedShow
Now

Proposals under this topic should aim to deliver results that are directed and tailored towards, and contribute to all of the following expected outcomes: - Patients with rare or very rare cancers or cancer subtypes have access to tailored, promising biomarker-guided medicines or multi-modal treatment interventions via participation in subsequent clinical trials or national or regional compassionate use programmes by health authorities; - Researchers, physicians, innovators, startup, spin-off and spin-out companies, SMEs, charities or foundations and other professionals from different disciplines and sectors have access to innovative technology, medical devices or promising biomarker-guided medicines for further validation or commercialisation; - National healthcare providers, policymakers and authorities in European regions, EU Member States and Associated Countries have early safety and efficacy evidence to support further testing of affordable biomarker-guided medicines or multi-modal treatment interventions that benefit patients with rare or very rare cancers in their healthcare systems;

16 October 2026scheme · version 2

Cycle
Cycle: AddedShow
Now

Uitslag van de evaluatie rond 5 maanden na de deadline; ondertekening van de subsidieovereenkomst rond 8 maanden na de deadline (General Annex F).

Cumulation
Cumulation: AddedShow
Now

Geen dubbele financiering: een actie kan maar één subsidie uit de EU-begroting krijgen (behalve EU Synergy grants) en dezelfde kosten mogen nooit bij twee verschillende EU-acties worden gedeclareerd (General Annex G).

Keywords
Added: biomarkergestuurde geneesmiddelen, EU-missie Cancer, fase 1-studies, Horizon Europe, HORIZON-MISS-2027-02-CANCER-03, zeldzame kankers
Required attachments
Added: Aanvraagformulier deel A: administratieve gegevens van de deelnemers en samengevatte begroting (online in te vullen); Aanvraagformulier deel B: technische beschrijving van het project (pdf, maximaal 45 pagina's); Gedetailleerde begrotingstabel (HE LS-sjabloon) voor de lump-sumbijdrage; Bijlage met informatie over de klinische studie(s) (HE-sjabloon); Bewijs van advies van regelgevende instanties over de opzet van de klinische studie(s)
Goals
Goals: 3 newShow
New

Toegang tot gerichte behandelingen Patiënten met zeldzame of zeer zeldzame kankers krijgen toegang tot veelbelovende biomarkergestuurde geneesmiddelen of multimodale behandelingen via vervolgstudies of compassionate-useprogramma's.

Kansen voor validatie en commercialisering Onderzoekers, artsen, start-ups, spin-offs, mkb, fondsen en andere professionals krijgen toegang tot innovatieve technologie, medische hulpmiddelen of geneesmiddelen voor verdere validatie of commercialisering.

Vroeg bewijs voor zorgbeleid Zorgaanbieders en beleidsmakers hebben vroeg bewijs over veiligheid en werkzaamheid om betaalbare biomarkergestuurde geneesmiddelen of multimodale behandelingen voor zeldzame kankers verder te testen.

7 October 2026scheme · version 1 · first publication

Source

Contact & source

Funding body
European Health and Digital Executive Agency
Last verified
17 November 2026 by the Twin editors
Start your application

Start your HORIZON-MISS-2027-02-CANCER-03 application
in Twin.

Twin helps you write your application, based on the scheme and your own project documents. You stay in control of every text.